Walter M. Stadler to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Walter M. Stadler has written about Antimetabolites, Antineoplastic.
Connection Strength
0.891
-
Treatment of metastatic urothelial cancer in the post-MVAC era. World J Urol. 2001 Apr; 19(2):126-32.
Score: 0.176
-
Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology. 1999 Feb; 53(2):243-50.
Score: 0.151
-
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997 Nov; 15(11):3394-8.
Score: 0.139
-
Metastatic bladder cancer: advances in treatment. Eur J Cancer. 1997 Jan; 33 Suppl 1:S23-6.
Score: 0.131
-
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94.
Score: 0.068
-
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.
Score: 0.052
-
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer. 2002 May 15; 94(10):2602-9.
Score: 0.047
-
Gemcitabine doublets in advanced urothelial cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 3):15-9.
Score: 0.047
-
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
Score: 0.045
-
New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol. 1998 Feb; 16(1):23-9.
Score: 0.035